C-reactive protein: clinical applications and proposals for a rational use  by Aguiar, Francisco J.B. et al.
REV ASSOC MED BRAS. 2013; 59(1):85-92
www.ramb.org.br
Revista da
ASSOCIAÇÃO MÉDICA BRASILEIRA
Review article
C-reactive protein: clinical applications and proposals for a 
rational use☆
Francisco J.B. Aguiara, Mario Ferreira-Júniorb, Maria M. Salesc, Luiz M. Cruz-Netoa,  
Luiz A.M. Fonsecad, Nairo M. Sumitac, Nilo J.C. Duartec, Arnaldo Lichtensteinb,*,  
Alberto J.S. Duartec
a Clinical Emergency Assistance, Hospital das Clínicas, Medical School, Universidade de São Paulo (USP), São Paulo, SP, Brazil
b General Practice and Propaedeutics, Hospital das Clínicas, Medical School, USP, São Paulo, SP, Brazil
c Central Laboratory Division-LIM03, Hospital das Clínicas, Medical School, USP, São Paulo, SP, Brazil
d Immunology Department, Hospital das Clínicas, Medical School, USP, São Paulo, SP, Brazil
ARTICLE INFO
Article history:
Received 2 May 2012
Accepted 10 July 2012
Keywords:
CRP
C-reactive protein
Laboratory tests
Clinical use
☆Study conducted at the Study Group for Rational Use of the Clinical Laboratory of the Hospital das Clínicas, Medical School, 
Universidade de São Paulo, São Paulo, SP, Brazil 
 *Corresponding author at: Rua Capote Valente, 127/101 – Pinheiros, 05409-000 – São Paulo, SP, Brazil  
 E-mail address: alichten@usp.br (A. Lichtenstein) 
0104-4230 © 2013 Elsevier Editora Ltda.
A B S T R A C T
C-reactive protein (CRP) is an acute-phase protein whose requests have been growing 
exponentially in several countries, including Brazil. In this study, the use of CRP in several 
clinical situations was reviewed by a group of physicians comprised by specialists in internal 
medicine, medical emergencies, intensive care, screening, and laboratory medicine, aiming 
to analyze the applicable literature and to propose guidelines for a more rational use of 
this laboratory test. The result was the creation of flowcharts guiding CRP request, adjusted 
to four different healthcare environments, namely, intensive care units, emergency room, 
wards, and outpatient clinics. These flowcharts, as well as a more detailed discussion on 
several clinical recommendations for the test, are presented in this study.
© 2013 Elsevier Editora Ltda.
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Proteína C reativa: aplicações clínicas e propostas para utilização racional
R E S U M O
A proteína C reativa (PCR) é uma das proteínas de fase aguda cuja solicitação tem crescido 
de forma exponencial em vários países, incluindo o Brasil. Neste estudo, a utilidade da 
PCR em diversas situações clínicas foi revisada por um grupo de médicos composto por 
especialistas em Medicina Interna, Emergências Médicas, Terapia Intensiva, Rastreamento 
e Medicina Laboratorial com o objetivo de analisar a literatura pertinente e propor diretrizes 
para o uso mais racional desse exame laboratorial. O resultado foi a criação de fluxogramas 
orientadores da solicitação de PCR adaptados a quatro ambientes assistenciais diferentes, 
sendo eles unidades de terapia intensiva, pronto-socorro, enfermarias e ambulatórios. 
Esses fluxogramas e uma discussão mais detalhada sobre as diversas indicações clínicas 
do exame são apresentados neste estudo.
© 2013 Elsevier Editora Ltda. 
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Clinical use of C-reactive protein and the 
erythrocyte sedimentation rate
C-reactive protein (CRP) is one of the acute-phase proteins 
(APPs), which are those whose serum level increases or 
decreases by at least 25% during inflammatory conditions. 
However, despite the name, they can also change during 
chronic inflammatory processes. Perrakos and Vincent 
identified 3,370 references, including clinical and experimental 
studies of 178 different APPs used as sepsis biomarkers.1 
Nonetheless, there are only two tests based on APPs 
measurement widely used today: erythrocyte sedimentation 
rate (ESR) and CRP.
ESR, which is the rate at which erythrocytes fall through 
plasma, depends on the concentration of fibrinogen (which 
is an APP), and is an indirect measure of this concentration. 
It  is  influenced by the shape,  size,  and number 
of erythrocytes, as well as by other plasma components, 
such as immunoglobulins. This may result in inaccuracy 
and error.2
CRP was discovered in 1930 and received this name because 
it reacted with the C-polysaccharide of pneumococcus in the 
acute phase of pneumococcal pneumonia. CRP measurement is, 
therefore, a direct determination of an APP and, in the presence 
of inflammatory conditions, its serum levels change rapidly 
and its variation is wider than that of ESR. During postoperative 
periods, it shows sensitivity to detect complications higher 
than increases in ESR, leukocytes, heart rate, or fever.3 Unlike 
ESR, CRP measurement does not change in the presence 
of anemia, polycythemia, spherocytosis, macrocytosis, 
congestive heart failure, or hypergammaglobulinemia.3 These 
characteristics are increasing CRP use in place of ESR, despite 
greater experience and familiarity with the latter. None of 
the tests are typically useful when assessing conditions with 
vague clinical presentation, although they are frequently 
used in this context; in any case, they should not be used to 
screen inflammation in asymptomatic individuals (possible 
exception: risk stratification for cardiovascular disease). In 
the presence of suggestive clinical evidence, it can be useful 
to screen for inflammatory conditions, however, without 
accurately distinguishing the etiologic mechanism. Increases 
occurr not only in infections, but also in the presence of 
systemic inflammation caused by rheumatoid arthritis, 
myocardial infarction, necrotizing pancreatitis, multiple 
trauma, neoplasias, vasculitis, and even possibly in some cases 
of serotonin syndrome, only to mention some conditions.
Often, CRP and ESR are used to establish baselines 
and subsequently to monitor the evolution of infectious, 
autoimmune, and other diseases. 
Dynamics of C-reative protein
CRP is predominantly secreted by the liver and starts four to 
six hours after the stimulus; it duplicates every eight hours, 
and peaks within 36 to 50 hours. CRP has a plasma half-life of 
19 hours, and even after a single stimulus, as in a trauma or 
surgery, it may take several days to return to the baselines.4 
For this reason, serial measurements over several days are 
more useful than isolated results.5 Thus, it is possible to note 
CRP’s limitations for monitoring of critical patients, as its level 
can be low or normal in the first 12 hours of fever in infectious 
processes. Conversely, due to its long half-life, it may remain 
high during the initial recovery phase, although some authors 
suggest that non-reduction after 48 to 72 hours of treatment or 
postoperative period requires a re-evaluation.4,5
Clinical conditions and change profiles
Generally, mild inflammations and viral infections lead to 
increases to the range of 10 to 40 mg/L, while more severe 
inflammations and bacterial infections lead to serum levels 
between 40 to 200 mg/L.6 In the present study, concentrations 
of CRP are expressed in mg/L, but they can also be expressed 
in mg/dL. There are studies evidencing that a serum level of 
100 mg/L would have a sensitivity of 80% to 85% for bacterial 
infection;2 however, severe viral infections may also result in 
increases of the serum level.5
Some authors suggest 50 to 100 mg/L as an optimal serum 
level to separate sepsis from systemic inflammatory response 
syndrome (SIRS).4 Povoa7 evidenced that a cutoff serum level of 
50 mg/L increases the chance of sepsis by four-fold. Pierrakos,1 
however, did not recommend the use of CRP to separate sepsis 
from inflammatory conditions, deeming it inaccurate for 
this purpose. The problem is not only the dynamics of CRP 
variations, already mentioned, but also the lack of a “gold 
standard” for the diagnosis of sepsis, which is defined by the 
association between clinical and laboratory data. In general, 
this makes the determination of biomarkers’ sensitivity and 
specificity harder in this clinical condition. In fact, some 
studies adopt culture-positive results as a gold standard, which 
is also questionable, as cases of culture-negative sepsis1 are 
frequent.
Also widely used in monitoring rheumatic diseases, CRP has 
the specific characteristic of not showing any increase with 
the activity of systemic lupus erythematous, except in the 
presence of serositis,8 chronic polyarthritis, or vasculitis with 
tissue infarction.9 In the absence of these characteristics, an 
increase suggests infection, and ESR should be chosen to detect 
the activity of the disease. Discrepancies like these are not rare 
among the variations of these active phase evidences; this is 
expected, as cytokines influence APP synthesis by hepatocytes, 
and serum levels of cytokines and other modulators of 
inflammatory responses vary pursuant to the disease and stage 
of clinical evolution. Other situations in which CRP may remain 
between 10 and 20 mg/L or even not increase are scleroderma, 
dermatomyositis, and ulcerative colitis.5
It can be concluded that there is not a single test to detect 
inflammation, and multiple measurements of CRP and ESR 
are frequently used. The interpretation will take into account 
several factors, among them the time profile of variations and 
the clinical context.
Currently, there is a high-sensitivity method (HS) for 
measurement of CRP concentrations. It measures CRP 
exactly the same as the conventional test, but is capable 
of detecting much lower CRP concentrations (detection 
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Box 1 – Clinical indications and limitations of the use of C-reactive protein.
Potential clinical situations Acute infection
Chronic infection
Postoperative period
Neoplasias
Acute cardiovascular disease
Non-infectious systemic inflammation (e.g., rheumatoid arthritis, lupus with serositis or vasculitis, multiple 
trauma, necrotizing pancreatitis)
Use of the analyte Support clinical diagnosis
Monitoring of inflammatory activity during clinical progress
Follow-up of the effectiveness of antibiotic or anti-inflammatory treatment
Detection of postoperative infectious complications
Potential prognostic indicator for coronary diseases
Expected Results Mild inflammations and viral infections: 10 to 40 mg/L
Severe inflammations and bacterial infections: 40 to 200 mg/L
Sepsis: higher than 50 mg/L
Limitations on the use It is not indicated for disease detection in asymptomatic patients or in the presence of vague symptoms
Any delay in its increase may cause an erroneous interpretation and slow the antibiotic or anti-inflammatory 
treatment
Low levels (10 to 20 mg/L) are found in scleroderma, dermatomyositis, ulcerative colitis, as well as in lupus 
without serositis or vasculitis
limit of 0.03 mg/L). The main practical consequence of 
the new methodology was expressed in the JUPITER study 
(Justification for the Use of Statins in Primary Prevention: 
an Intervention Trial Evaluating Rosuvastatin) published 
in 2008.10 This interventional trial followed almost 18,000 
individuals and observed that statins reduced infarctions and 
cerebrovascular accidents in individuals without any heart 
disease or hypercholesterolemia, but with changes in serum 
level obtained through HS-CRP. Regardless of controversies 
regarding the amount of evidence, HS-measurement has 
been used since then to support the decision to use statins 
in primary prevention. The pharmaceutical company that 
manufactures rosuvastatin financed the study, and its main 
author is connected to the laboratory, in addition of holding 
patents related to the use of inflammatory biomarkers to 
treat heart diseases, including the use of the HS method for 
cardiovascular risk assessment.9
The HS method has also been used to prognosticate stable 
coronary disease and acute coronary syndrome.11-18 However, 
these results are being questioned.19
These data show that the measurement of CRP can be 
useful to the physician if wisely requested; they also show that 
knowledge of CRP dynamics, as well as its limitations, is critical 
for the interpretation of its results. Clinical indications for the 
use of CRP, as well as some limitations, can be found in Box 1.
Healthcare singularities of intensive care units 
(ICUs), wards, emergency rooms (ERs), and 
general outpatient clinics
ICUs, wards, ERs, and outpatient clinics are different 
environments, serving a spectrum ranging from critical 
patients in an ICU to healthy individuals seeking an outpatient 
clinic for medical check-ups. The prevalence and severity 
of diseases differ greatly among these places. This fact has 
consequences on requests for tests and their interpretation, 
e.g.: the lower the probability of the disease, the higher will 
be the probability for a positive test to be a false positive, a 
frequent situation in asymptomatic outpatients. Inversely, in 
patients presenting serious conditions with a high probability 
of comorbidities, a negative test has a higher probability of 
being a false negative. These principles are applied to the 
interpretation of any test (except in the unusual event of a 
test with sensitivity and/or specificity of 100%). 
Serial measurement (at minimum time intervals of 24 
hours) should be restricted to critically ill patients. Some of 
these patients are in coma and/or on mechanical ventilation, 
i.e., with conditions that make clinical evaluation harder; in 
this environment, the increased risk of infections associated 
with procedures and clinical conditions justifies this 
initiative.  
Even with the limitations mentioned above, in the Hospital 
das Clínicas, Medical School, Universidade de São Paulo, 
in São Paulo, a tertiary level hospital comprising several 
environments, such as outpatient clinics, wards, ICUs and 
an ER, the number of CRP requests jumped from 50,365 in 
2006 to 254,817 in 2011, representing an increase of 405%. 
The highest annual relative increase (70%) occurred between 
2006 and 2007, before the publication of the JUPITER study, 
whose recommendations led to an increase in the HS-CRP 
measurement method. The highest number of CRP requests 
occurs in the ER and ICUs. Part of this increase is not supported 
by a proper clinical indication and this entails increasing costs, 
with no benefits to the patients. 
A study by Santos et al., regarding CRP requests in an ER 
of a university hospital, where a significant increase was also 
verified, found that 25% of the requests were related to the 
diagnostic investigation of pneumonia, and 13.5% were related 
to investigation of fever.20
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Justifications and objectives 
Considering that the number of requests for serum 
measurement of CRP is proving to be excessive and often 
inappropriate, resulting in distress and risks to patients, in 
addition to increasing costs, it was decided to perform this 
study, whose objectives are to contribute to:
r Improve the quality of care provided to patients by 
reducing the distress caused by blood collections, by 
reducing the chance of false positive results, and by 
limiting any mistaken diagnostic and/or therapeutic 
consequences.
r Improve medical knowledge, by offering guidelines 
regarding the indications for CRP requests, and reducing 
excessive requests in order to make this practice more 
reasonable and effective. 
r Reduce laboratory expenses with this analyte, allowing 
for the implementation of other diagnostic parameters, 
including those evidencing inflammation and infection.
Method and procedure
In September 2010, the Central Laboratory Division (Divisão 
de Laboratório Central –DLC) of the HC-FMUSP gathered a 
multidisciplinary group of specialists in internal medicine, 
medical emergencies, intensive care, outpatient clinic, and 
laboratory medicine aiming at studying ways to improve the 
pattern of requests for laboratory tests and, thus, try to avoid 
or mitigate risks associated with their inappropriate use, 
such as, e.g.: spoliation of patient; overdiagnosis; mistaken 
diagnoses (false positive and false negative); overtreatment; 
patient depression or anxiety; poor cost-effective methods; and 
waste of financial resources.
Coordinated by the Director of the DLC, eight physicians 
were invited – all working at HC-FMUSP, with experience 
in assisting patients in their respective areas, and with the 
support of three residents in internal medicine and laboratory 
medicine- to prepare the “Rational Use of Clinical Laboratory” 
project. As part of the project development, the group met on 
a weekly basis, from January to December, 2011, to analyze 
studies, recommendations, and guidelines published in the 
national and international scientific literature, and to discuss 
and establish practical criteria involving the request, at first, 
for the following laboratory tests: 1) HS and regular CRP; 2) 
ionic and total calcium; 3) thyroid-stimulating hormone (TSH, 
and free T4); 4) vitamin D; 5) blood cultures for aerobic and 
anaerobic microorganisms. The tests above were chosen 
because they are among the most requested in the HC-FMUSP, 
being part of curve A, which comprises laboratory tests whose 
sum corresponds to 80% of the DLC’s demand. However, 
the purpose of this study was only to analyze and establish 
flowcharts to guide the rational use of high-sensitivity CRP or 
conventional CRP, leaving other tests mentioned above, also 
studied by this group, for later considerations. 
Thus, the study was based on publications regarding the 
measurements of CRP through conventional methods and HS, 
directed to: 
r Clinical practice in the contexts of urgent care, 
emergency, ward, and ambulatory medicine; medical 
assistance; or preventive medicine; 
r Undergraduate and postgraduate medical schools; 
r Analysis of the financial impact of the tests requested.
It was a non-systematic review of the literature, in which 
the following keywords were used: C-reactive protein, high-
sensitivity C-reactive protein, infection, inflammation, 
coronary disease. The 76 studies chosen were divided among 
the participants of the groups, and were presented and 
discussed during the weekly two-hour meetings, while their 
findings were recorded and systematized by the resident in 
laboratory medicine. 
The decision flowchart was the manner by which the 
group decided to consolidate and present the results of its 
work. The reasons that led to such decision were: a) ease of 
viewing the situations in which CRP requests are indicated, 
and those in which its repetition is allowed/recommended; 
b) adaptation for use in different medical contexts (ICU, ER, 
ward, outpatient clinic); c) potential improvement or detailing 
based on basic clinical situations, both general and specific, 
in a single flowchart; d) dynamism and explanatory potential, 
which allows for the inclusion  of alerts, electronically blocking 
unnecessary repetitions. Additionally, the decision flowchart, 
which summarizes both the formal scientific knowledge 
accumulated and published and the clinical experience of the 
participants in the working group, may facilitate dialogue with 
personnel of other areas also involved in the test request, such 
as, e.g., information technology (IT), management, operational, 
and cost control departments of the clinical laboratory itself.
The drawing of each step of the flowchart was carefully 
planned, analyzed, and discussed by the group, and the 
definition of its current format, presented herein, corresponds 
to the internal consensus resulting from the analysis of 
available scientific evidence based on the clinical practice of 
all participants.
The value of the experiences based on evidences20,21 and 
the establishment of guidelines22 in order to rationalize and 
eventually reduce unnecessary test requests is demonstrated 
in some studies. Thus, by acting in a teaching hospital, in 
addition to exploring the teaching potential of flowcharts, the 
group sought to associate its implementation with discussions 
regarding the use and interpretation of CRP with undergraduate 
students, residents, and medical staff. 
Results and comments
Figs. 1 and 2 present the decision flowcharts for CRP requests 
in several contexts of medical assistance: ICU, ER, ward, and 
outpatient clinic.
Fig. 1 shows the recommendations for measurement in ICU 
patients. Considering the clinical vulnerability of some of these 
patients and the risks associated with certain procedures, 
daily CRP measurement may be useful for the complementary 
diagnosis of acute infections. Monitoring of its daily curve (at 
minimum time intervals of 24 hours), with verification of a 
trend of reduction or increase, provided additional data to 
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Revaluate the 
indication
Revaluate the 
indication
YES
YESNO
Patient shows any of these 
during progress:
 CRP decrease
 Clinical stability
Recommended 
repetition: 
Every 24 h
Emergency room
HS-CRP CRP
Well-defined severe acute 
infection, with indication for 
hospitalization
HS-CRP is not indicated for critically ill 
patients. Always request regular CRP.
Recommended repetition: 
Every 24 h
Not recommended for 
inpatients
Intensive care unit
HS-CRP CRP
Critically ill patient and/or patient 
presents any of the following 
situations: 
Postoperative
High risk for acute infection due to:  
     Mechanical ventilation
     Airway aspiration
HS-CRP is not indicated for critically 
ill patients. Always request regular 
CRP.
Fig. 1 – Flowchart for C reative protein request in 
emergency rooms and intensive care units.  
HS-CRP, high-sensitivity C reactive protein;  
CRP, C reactive protein.
the daily clinical evaluation of the patient. Measurement 
should not be performed in intervals shorter than 24 hours. 
HS-measurement is never indicated for evaluation of a 
potential infectious complication. 
Recently, HS-CRP measurement was suggested as a 
prognostic indicator of cardiac outcomes in individuals with 
stable coronary disease (SCD) or acute coronary syndrome 
(ACS); however, current scientific evidences are not enough 
to recommend it as a way to determine the application of 
specific therapies for ACS or for secondary prevention of 
coronary events, which makes its request questionable in 
such cases.23
The situations in which CRP measurement may be useful in 
an ER context are indicated in Fig. 1. Much has been published 
regarding CRP in ERs; however, there are few evidences of its 
value in this environment.24-27 This analysis will be assessed 
in the specific situations in which it was studied:
Non-traumatic abdominal pain: in 2007, Bundy et al.28 
published a literature review regarding diagnostic methods for 
acute appendicitis in children. The CRP value was classified as 
inconsistent. Retrospective studies, such as those by Chen and 
Wang29 and by Wu et al.,30 analyzed CRP cutoff values versus 
surgical findings, showing a good correlation; however, these 
publications did not addressed CRP as a variable for surgical 
indication. In adults, other diagnoses in addition to appendicitis 
may be the cause of inflammatory acute abdomen, such as 
uncomplicated diverticulitis without surgical indication. It can 
be concluded that medical history, physical examination, and 
imaging methods are more relevant diagnostic procedures in 
this clinical condition. If CRP measurement is chosen, the daily 
curve evolution must also be interpreted.
As a predictor of mortality: for patients presenting apparent 
severity criteria, initial CRP followed by daily curve represents 
an additional index among others already studied. We note 
that, in this work, CRP is not studied as a discriminative factor 
for hospitalization, but as a prognostic factor in populations 
where the hospitalization decision has already been taken; 
nevertheless, the study by Lee et al.8 shows that CRP 
underperforms the clinical score.
Pneumonia: although included in guidelines for evaluation 
of patients with community-acquired pneumonia, CRP value 
as a discriminative factor of essential specific decisions, 
e.g., hospitalization versus home care, was not satisfactorily 
studied. It is worth noting that this criterion still contemplates 
a clinical score. Gonzales et al.9 evaluate the use of CRP 
regarding the physician’s decision to prescribe antibiotics for 
patients complaining about acute cough; their finding was that 
the use of CRP did not affect this decision. Once again, the 
suggestion of this study is that CRP should be requested for 
patients with pneumonia that will be hospitalized pursuant 
to traditional decision criteria. It is worth mentioning that the 
diagnosis of pneumonia requires imaging tests.
Patient with fever, with no defined focus: Lee et al.31,32 
pointed out the need to understand the dynamics of CRP 
when evaluating its results; hence, patients with early fever 
symptoms for less than 12 hours may present low CRP 
values; this does not mean a non-severe condition. In these 
circumstances, the overestimation of laboratory results 
may result in error. As already mentioned, the clinical score 
provides better performance when evaluating severity, in 
comparison with CRP value alone.
Finally, it is suggested that the use of CRP measurement 
in ERs is reserved for acute infectious syndromes showing 
clinical indication for hospitalization.
For inpatients in medical wards (Fig. 2), especially in the 
stage of diagnostic investigation of a systemic inflammatory 
disease or unidentified acute infection (e.g., fever of 
unknown origin), with or without identifiable risk factors 
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YES
Recommended 
repetition: 
Every outpatient 
appointment
Ward
HS-CRP CRP
Patient with suspected or in a 
clinical treatment of:
 Systemic inflammatory disease
 Acute or chronic infection
Scientific evidences indicate that 
HS-CRP provides no satisfactory 
predictive value in the screening for 
CAD in the general population.
Re Revaluate 
the indication
NO
Fig. 2 – Flowchart for C reative protein request in outpatient 
clinics and wards.  
HS-CRP, high-sensitivity C reactive protein; CAD, coronary 
artery disease; CRP, C reactive protein.
(e.g., risk for aspiration through airways or central vascular 
catheter), daily repetition of the measurement may be 
useful, especially while the clinical condition is undefined 
or unstable. In cases of definition of a diagnosis or when the 
patient is stable, repetition should either be suppressed or 
its frequency reduced at the assistant physician’s discretion. 
In the situations mentioned above, HS-CRP measurement 
method is not justified. 
The admission, in medical wards, of patients with a 
previously known condition of stable coronary disease also 
does not justify, by itself, the indication of HS-measurement.23
Finally, Fig. 2 summarizes the clinical situations in 
which CRP measurement is indicated as part of a diagnostic 
investigation or long-term follow-up of a known disease in an 
outpatient clinic. In cases of strong suspicion of a systemic 
inflammatory disease or acute or chronic infection, high CRP 
is an unspecific complementary indicator of the disease; 
however, based on current knowledge, it is not possible 
to define standards capable of specifically differentiating 
between inflammatory and infectious diseases, nor between 
bacterial and viral diseases5 (Box 1). In cases of inflammatory 
or chronic infectious disease already diagnosed, periodic 
repetition of CRP (e.g., at each visit for an outpatient 
appointment) may help to indicate the presence of the disease 
or the impact of the treatment. 
Recently, the association of coronary disease with high 
CRP serum levels measured through HS (normal cutoff: 3.0 
mg/L) and its potential role as an additional indicator in the 
stratification of cardiovascular risk provided by predictive 
models (e.g., Framingham score) induced an increase in 
test requests at outpatient clinics. However, due to the lack 
of sufficient scientific evidence showing that the reduction 
in CRP serum concentrations prevents secondary coronary 
events, its request is questionable, even for patients with 
well-diagnosed cardiovascular disease (CVD). There are also no 
conclusive evidences that HS-CRP measurement in a primary 
screening for cardiovascular disease can modify the morbidity 
or mortality trend of the general population.33,34
Discussion
The recent diversification of the repertoire of complementary 
diagnostic and clinical follow-up tests, with state-of-the art 
and sophisticated techniques, is certainly contributing to 
improve medical care. Conversely, in several situations, the 
excessive request for laboratory tests may result in additional 
health problems, and in the spending of financial resources 
that could be better applied. The main causes of the growing 
demand for laboratory tests are:
1. Overestimation of the laboratory test rather than 
physical examination or medical history;
2. Defensive medical posture;
3. Failure to comply with a basic principle: before requesting 
a test, the physician must evaluate whether it will bring 
additional information;
4. Professional insecurity or inexperience;
5. Reduced time of medical appointments;
6. Standardization of “medical check-ups” (tests requested 
as part of a standard “routine” and not on a selective 
basis, case by case);
7. Aging of the world’s population, with the resulting 
increase in comorbidities;
8. Emergence of new tests for early detection of high 
morbidity and chronic diseases in asymptomatic 
individuals (screening or check-up);
9. Influence of the media and conflicts of interest;
10. Lack of guidelines in educational institutions;
11. Lack of knowledge of procedure costs.
CRP measurement in university hospitals and in exclusively 
healthcare-only hospitals is showing a strong trend of increase 
in requests, but the process had not been critically evaluated 
until now. In this regard, it is possible that the availability of 
the HS method, which enables the detection of considerably 
lower CRP serum levels, may be providing physicians with 
a false feeling of having a more accurate method than the 
former, thus encouraging its general request, even in situations 
where it is not indicated, as in cases of diagnosis or monitoring 
of acute or chronic inflammatory or infectious diseases.
Having been recently introduced into the clinical practice, 
HS-CRP measurement still requires a set of evidences that 
conclusively supports recommendations or guidelines for 
its use, especially when addressing cases of coronary artery 
disease, which appears to be its main clinical use, although 
still vaguely defined.
The presentation of these decision flowcharts for CRP 
requests in the ICU, ER, ward, and outpatient clinic contexts 
may be the first initiative to contribute to the establishment of 
guidelines for these requests. They intend to guide physicians, 
medical students, and residents as to the main test indications 
and their frequency, encouraging a healthy reflection on the 
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actual need to request them and the impact on the medical 
conduct to be adopted. As a general rule, if there is a high 
probability that the conduct will not take into account the test 
result, its request should be avoided, thereby preventing errors 
in clinical reasoning.
The guided indication of CRP measurement may have a 
determining effect on health and progress of clinical cases, as it 
helps to avoid interpretation errors and improper interventions, 
such as in the case of CRP requests at intervals shorter than 
24 h for ICU or ER patients with inflammatory or infectious 
diseases, or even in the use of HS-measurement to screen 
CVD in the general population. It is important to remember 
that examinations erroneously interpreted as normal (false 
negative) provide the physician and the patient a false feeling 
of safety, while examinations erroneously interpreted as 
abnormal (false positive) may generate a “snowball” of other 
diagnostic procedures, many of them invasive, with potential 
risk of health hazards. The same may occur when treatment 
is changed without clinical justifications, based only on non-
significant alterations in the indicators of inflammatory activity.
Finally, flowcharts may be useful to healthcare providers 
focused on maintaining the good quality of the health care 
provided to clients covered by the service, while conserving 
financial resources. Calculated in a simple way, HS-CRP 
measurement costs on average five times more than regular 
CRP measurement. Therefore, if improperly requested at 
a high frequency, its impact on the clinic’s total expenses 
may be significant, and may grow exponentially over the 
hospitalization or outpatient follow-up period. Add to this the 
unnecessary costs of other diagnostic or therapeutic procedures 
indicated by false positives, or the costs of complications or 
sequelae of erroneously applied examinations or treatments, 
and the expenses can reach extremely high levels.
This study was a preliminary attempt to promote the rational 
use of CRP laboratory measurements, based on available scientific 
evidence and on the clinical experience of a multidisciplinary 
group of physicians who are familiar with the topic. 
The possible limitations of the current stage of the decision 
flowcharts presented in this work are as follows: 1) lack of a 
systematic and complete review of the literature that, although 
desirable, could excessively delayed disclosure of the study, 
due to its complexity, without ensuring added value to the 
guided review performed; 2) impossibility, until now, to test the 
proposed flowcharts in the clinical practice of ICU, ER, medical 
wards, hospital outpatient clinics, and other exclusive public 
and private healthcare, university, or assistance services, which 
may represent a barrier for its implementation.
Conversely, the disclosure of the flowcharts in their current 
stage of development may enable medical professionals to test 
them in their specific professional contexts and to improve 
them based on their own experiences.
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